Search Allelic Imbalance of Expression of BRCA Genes in Hereditary Risk of Breast and/or Ovarian Cancer
NCT ID: NCT01333748
Last Updated: 2012-07-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
530 participants
INTERVENTIONAL
2010-04-30
2012-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients group
Patients with ovarian and/or breast cancer
blood collection
blood collection for research quantification of allelic expression in the gene BRCA1.
control population
control population without history of breast and/or ovarian cancer
blood collection
blood collection for research quantification of allelic expression in the gene BRCA1.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
blood collection
blood collection for research quantification of allelic expression in the gene BRCA1.
blood collection
blood collection for research quantification of allelic expression in the gene BRCA1.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Women with breast cancer and / or ovarian cancer meet criteria suggestive of a hereditary predisposition
* Deleterious mutation of BRCA1 and BRCA2 sought and not highlighted
* Age ≥ 18 years
* Agreeing to participate in the study (a collection of signed informed consent)
For control population
* Women with no history of breast and / or ovarian cancer and no family history of breast and / or ovarian cancer among family members on the 1st and 2nd degree before age 50 for breast cancer and before 60 years for ovarian cancer
* Agreeing to participate in the study (a collection of signed informed consent)
Exclusion Criteria
* Patients with a known deleterious mutation in BRCA1 and BRCA2
* Patients do not meet criteria suggestive of a hereditary predisposition
* Persons deprived of liberty or under guardianship (including guardianship)
For control population:
* Males
* Personal or family history of breast and / or ovarian cancer (breast or ovarian cancer in their family experienced 1st and 2nd degree before age 50 for breast cancer before age 60 for cancer ovarian)
* Persons deprived of liberty or under guardianship (including guardianship)
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Francois Baclesse
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Centre François BACLESSE
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Agnès HARDOUIN, MD
Role: PRINCIPAL_INVESTIGATOR
Centre François Baclesse
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dr Pascaline BERTHET
Caen, Caen, France
Centre Eugène MARQUIS
Rennes, Rennes, France
Centre Hospitalier
Cherbourg, , France
CHU
Rennes, , France
Centre Henri BECQUEREL
Rouen, , France
CHU
Rouen, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009-A00833-54
Identifier Type: REGISTRY
Identifier Source: secondary_id
EXSAL
Identifier Type: -
Identifier Source: org_study_id